Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269670 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Everolimus Beyond Progression
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02269670 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 3 participants.
The verdict
NCT02269670, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement (recurred) on everolimus and exemestane hormone therapy. Everolimus is a chemotherapy drug that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen and progesterone are hormones that can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by lowering the amount of estrogen and progesterone the body makes. Giving everolimus with a different type of hormone therapy may be an effective treatment for breast cancer in patients who progressed on everolimus with exemestane.
Interventions
- DRUG letrozole
- DRUG fulvestrant
- DRUG everolimus
- DRUG anastrozole
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-11-25 |
| Est. Completion | 2021-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02269670
The ClinicalTrials.gov registry entry for NCT02269670 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which letrozole is the first listed.
NCT02269670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02269670 about?
NCT02269670 is a clinical study titled "Phase II Study of Everolimus Beyond Progression". This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement (recurred) on everolimus and exemestane hormone therapy. Everolimus is a chem...
What is the current status of trial NCT02269670?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-11-25. Estimated completion is 2021-01-25.
What interventions are being tested in trial NCT02269670?
The interventions under investigation include: letrozole (DRUG), fulvestrant (DRUG), everolimus (DRUG), anastrozole (DRUG), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT02269670?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.